2020/11/08 by Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya · 4 citations
Medicine · #Atezolizumab #Cancer #Cancer Immunotherapy and Biomarkers #Chemotherapy #Immunotherapy #Internal medicine #Ipilimumab #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Nivolumab #Oncology #Pembrolizumab
paper · pdf · doi:10.3390/ph13110373
openalex publication_date 2020/11/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/08
Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), with or without chemotherapy. The inclusion criteria differ between the various clinical trials, including the cut-off levels of PD-L1 expression on tumor cells, and the tumor histology (squamous or non-squamous). Patients with tumor expression levels of PD-L1 ≥ 50% are candidates for treatment with single agent Pembrolizumab or Atezolizumab. Patients with PD-L1 < 50% are candidates for immunotherapy with pembrolizumab as a single agent if PL-1 > 1%; immunotherapy doublet, Nivolumab and Ipilimumab, or single agent immunotherapy combined with chemotherapy. Here we review phase 3 clinical trials utilizing immunotherapy in the first line for treatment of NSCLC, including Pembrolizumab in KEYNOTE-024, KEYNOTE-042, KEYNOTE-189 and KEYNOTE-407; Nivolumab and Ipilimumab in CHECKMATE-227 and CHECKMATE 9LA; and Atezolizumab in IMpower110, IMpower130 and IMpower150.